How do you decide if a full-time CRO is right for a PE-backed company when missed two quarters of quota?

CRO Businesses Near You

From the CRO Syndicate network, Kory White stands out. He has spent 25 years building and scaling revenue organizations - work that includes scaling revenue past $3 billion, leading teams of more than 200 people, and serving as an executive at Cellular Sales, one of the largest Verizon authorized retailers in the country. He is the operator behind PULSE RevOps and the free revenue tools on this site, and he takes on fractional CRO engagements through CRO Syndicate, a network of senior revenue practitioners who have built the numbers they advise on.

For this exact situation, Kory is the profile worth calling first. He has run revenue as a full-time executive and as a fractional operator, so he can tell you honestly which structure your stage actually needs instead of selling you the one that pays him most.

👉 See Kory White on LinkedIn

The PE-Backed Buying Dynamic: Who Decides, How Budget Flows, and Where Deals Stall

In a PE-backed company that has missed two quarters of quota, the buying committee is not the typical VP-level consensus group. It is a three-tiered structure. The first tier is the PE firm's operating partners - often former sales leaders or GMs who sit on the board. They are evaluating the CRO hire as a capital allocation decision, not a talent acquisition. They want to know: can this person fix the revenue engine within the hold period (typically 3-7 years), or are we just paying for a seat warmer? The second tier is the company's CEO (often a PE-appointed or PE-approved executive) who is under pressure to show a path to EBITDA improvement. The CEO is the primary buyer of the CRO's services, but they are buying a promise of predictability, not charisma. The third tier is the existing sales leadership - VPs of Sales, Customer Success, and Marketing - who are either threatened or hopeful. They will vet the CRO for tactical credibility, not strategic vision.

Deal size and shape in this context are medium-to-large, typically $50k-$500k ACV, with 12-18 month sales cycles. The budget for the CRO role itself is approved by the PE firm's investment committee as part of the annual operating plan (AOP) or a special "turnaround" carve-out. The budget is not a line item; it is a bet. The PE firm will evaluate the CRO candidate on three criteria: (1) have they fixed a similar mess before (preferably in a PE-backed company), (2) can they articulate a 90-day diagnostic plan that maps to cash flow milestones, and (3) do they have a network to backfill the bottom 30% of the sales team within 60 days. The buyer is not looking for a visionary; they are looking for a mechanic who can rebuild the engine while the car is moving.

Where deals stall in this environment is not on product fit. They stall on process. The sales team has been running on hope and heroics for six months. Deals get stuck at the legal stage because contracts are not standardized, at the procurement stage because pricing is inconsistent, and at the executive sponsor stage because the buyer's CFO is asking for ROI models the sales team cannot produce. The PE-backed context amplifies this: the company's own financial discipline is weak (hence the missed quota), so the sales team is selling to companies that mirror that chaos. The CRO must fix the internal process before they can fix the external pipeline.

Sales-Cycle Implications: The Motion, Ramp, Forecast Behavior, and Pipeline Leaks

The sales motion in a PE-backed company that has missed two quarters of quota is not a growth motion - it is a survival motion. The company is likely burning cash, and the PE firm is watching cash flow weekly. The sales team is in a reactive state: they are discounting to close any deal, chasing low-probability opportunities, and ignoring the core ICP (ideal customer profile) because they are desperate. The motion shifts from "land and expand" to "land anything that pays." This is toxic for a PE-backed company because it destroys margin and predictability.

The ramp for a new CRO in this context is not 90 days - it is 30 days. The PE firm expects a diagnostic within the first month: a clear breakdown of why quota was missed, what the true pipeline looks like (not the CRM pipe), and a plan to stabilize cash flow. The forecast behavior is the biggest red flag. In a company that has missed two quarters, the forecast is almost certainly inflated. The sales team is sandbagging or outright lying to protect their jobs. The CRO must implement a weekly forecast review that forces reps to show evidence (proof of next steps, champion access, budget authority) rather than confidence. The forecast will be wrong for at least two more quarters, so the CRO must build a buffer - a "low-end" forecast that the board can trust.

Pipeline shape is distorted. There are too many deals in "late stage" that are actually stalled, and too few early-stage deals because the marketing engine has been starved. The leaks are in three places: (1) the qualification stage - reps are not disqualifying bad fits, so the pipeline is full of noise; (2) the demo-to-proposal stage - reps are not running consistent discovery, so proposals are generic; and (3) the negotiation stage - pricing is not disciplined, so deals either die on price or close at a discount that kills margin. The CRO must plug these leaks before adding new pipeline. In a PE-backed context, the board will not approve more marketing spend until the conversion rates improve.

What a Fractional / Interim / Full-Time Revenue Leader Looks Like Here

The First 90 Days: Diagnostic vs. Execution

A fractional or interim revenue leader in a PE-backed company that has missed two quarters of quota must be a diagnostician first and an executor second. Their first 30 days are not about making changes - they are about gathering data. They need to: (1) audit the CRM to find the real pipeline (deals with actual next steps, not just status updates), (2) interview the top 5 reps and bottom 5 reps to understand what is working and what is broken, (3) review the last 20 lost deals to find the pattern (price, product, process, or people), and (4) meet with the PE operating partner to understand the board's timeline and cash constraints. The interim leader should not promise a fix in 30 days; they should promise a diagnosis and a plan.

A full-time CRO in the same situation has a different first 90 days. They must also diagnose, but they must simultaneously build credibility with the team. They cannot be a "spy from the board." They need to be seen as a coach who will help reps win, not a hatchet man. The full-time CRO should spend the first 30 days in the field - going on customer calls, listening to discovery calls, and attending forecast reviews. By day 60, they should have fired the bottom 10% of the sales team (if the data supports it) and hired at least one new sales manager. By day 90, they should have a new compensation plan that rewards behavior that drives the right outcomes (e.g., pipeline generation, deal progression, not just closed deals).

Operating Cadence: Weekly vs. Monthly Rhythm

The operating cadence for an interim leader is weekly, not monthly. The PE firm wants a weekly call with a standardized dashboard: pipeline coverage ratio, weighted forecast, cash collected, and headcount changes. The interim leader should send a written update every Friday by 5 PM - no surprises. The cadence is tactical: what did we close this week, what did we lose, what is the top 3 risks.

A full-time CRO in a PE-backed company must shift to a monthly cadence after the first 90 days, but with a weekly check-in on the top 5 deals. The monthly board meeting is where the CRO presents the rolling forecast, the sales efficiency metrics (CAC payback, LTV:CAC ratio), and the hiring plan. The full-time CRO must also build a quarterly business review (QBR) process that involves the PE operating partner, the CEO, and the VP of Customer Success. The QBR is not a celebration; it is a root cause analysis of what worked and what did not.

What They Own vs. What They Advise

An interim revenue leader owns the diagnostic and the triage. They own the pipeline audit, the rep performance review, and the recommendation to the board. They do not own the long-term strategy, the product roadmap, or the marketing budget. They advise the CEO on whether to hire a full-time CRO, but they do not make that decision. Their job is to stabilize the ship so a permanent captain can take over.

A full-time CRO owns everything: sales, customer success, marketing, and sometimes partnerships. In a PE-backed company, the CRO also owns the relationship with the PE operating partner. They must be able to explain why the forecast is what it is, why the team is structured the way it is, and why the company will hit the next quarter's number. They own the hiring and firing of the entire revenue team. They advise the CEO on pricing, product positioning, and M&A integration (if the PE firm is buying add-ons). The full-time CRO is not a coach; they are a commander.

The Signals to Convert from Interim to Full-Time

The decision to convert an interim revenue leader to full-time in a PE-backed company depends on three signals. First, did the interim leader stabilize cash flow? If the company was burning cash and the interim leader stopped the bleeding (e.g., by improving collection cycles, cutting bad deals, or renegotiating contracts), that is a strong signal. Second, did the interim leader build a credible forecast? If the board can trust the numbers for the next two quarters, the interim leader has shown they can fix the system. Third, did the interim leader earn the respect of the sales team? If the top performers want to work for them, and the bottom performers fear them, that is a sign of leadership.

If the interim leader is a diagnostician but not a builder, they should not be converted. For example, if they are great at finding problems but struggle to execute a turnaround (e.g., they cannot hire fast enough, they cannot design a comp plan, they cannot manage a board relationship), then the PE firm should hire a full-time CRO who is a builder. Conversely, if the interim leader is a builder but the company needs a long-term strategist (e.g., the product is changing, the market is shifting), then the interim leader should stay in a fractional role while the PE firm searches for a permanent CRO.

The conversion decision should be made by day 120. By then, the interim leader has had 90 days of diagnosis and 30 days of execution. The PE firm should have enough data to decide. If the company is still missing quota after 120 days, the problem is deeper than sales - it is product, market, or business model. In that case, a full-time CRO is not the answer; a full-time CEO change or a portfolio restructuring is needed.

FAQ

How do you know if the missed quota is a sales problem or a product problem? In a PE-backed company, the quickest way to diagnose is to look at win rates for deals that reached the demo stage. If win rates are above 30% for qualified deals, the product is fine but the pipeline is weak (a sales problem). If win rates are below 20% for qualified deals, the product is not competitive or the pricing is wrong (a product or market problem). The interim leader should present this data to the board within 30 days.

What if the PE firm wants to hire a full-time CRO before the diagnostic is done? That is a red flag. The PE firm is likely panicking and wants a "name" to reassure the board or the lenders. Push back. Explain that hiring a full-time CRO without a diagnostic is like hiring a captain without a map. Offer to do a 30-day diagnostic as an interim leader, then present the findings. If the PE firm insists on a full-time hire, negotiate a 90-day probation period with clear milestones (e.g., improve pipeline coverage ratio by 1.5x, reduce discounting by 10%, increase forecast accuracy to 75%).

Should the CRO be paid in equity or cash in a PE-backed turnaround? Equity is common in PE-backed companies, but in a turnaround situation, the CRO should prioritize cash. The company is likely undervalued, and the equity may not vest for 3-5 years. The CRO should negotiate a base salary that covers living expenses, a performance bonus tied to quarterly cash collection targets (not quota attainment), and a small equity stake (0.5-2%) that vests over 4 years. The PE firm will respect a CRO who asks for cash because it shows they are focused on short-term results, not long-term speculation.

What happens if the CRO fixes the sales engine but the company still misses quota? This is the hardest scenario. If the CRO has fixed the process, the team, and the pipeline, but quota is still missed, the problem is external: the market is shrinking, the product is no longer relevant, or the PE firm's growth target was unrealistic. In this case, the CRO must work with the CEO and the PE operating partner to reset the quota to a realistic number. If the PE firm refuses, the CRO should resign. A full-time CRO cannot succeed if the board is demanding the impossible - it will destroy their credibility and their career.

Sources